Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 Phase 1 dose-escalation in healthy subjects
NCT06625710Phase 1Completed
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Aug 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tertomotide in neurodegenerative disease (7 arms), sponsored by GemVax & KAEL Co., Ltd. Primary endpoints: Safety and Tolerability of GV1001 at 6 weeks and Pharmacokinetic Characteristics of GV1001 at 2 weeks. Started Oct 2024; status: completed.
02
Drugs
tertomotide
03
Conditions
neurodegenerative disease
Beyond the preview
Go deeper on NCT06625710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625710.